These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7974622)

  • 1. Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home.
    Vinks AA; Touw DJ; Heijerman HG; Danhof M; de Leede GP; Bakker W
    Ther Drug Monit; 1994 Aug; 16(4):341-8. PubMed ID: 7974622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics.
    Vinks AA; Brimicombe RW; Heijerman HG; Bakker W
    J Antimicrob Chemother; 1997 Jul; 40(1):125-33. PubMed ID: 9249216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis.
    Bosso JA; Bonapace CR; Flume PA; White RL
    Pharmacotherapy; 1999 May; 19(5):620-6. PubMed ID: 10331825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children.
    Rappaz I; Decosterd LA; Bille J; Pilet M; Bélaz N; Roulet M
    Eur J Pediatr; 2000 Dec; 159(12):919-25. PubMed ID: 11131352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime disposition in acute and stable cystic fibrosis.
    Leeder JS; Spino M; Isles AF; Tesoro AM; Gold R; MacLeod SM
    Clin Pharmacol Ther; 1984 Sep; 36(3):355-62. PubMed ID: 6432400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers.
    Mouton JW; Horrevorts AM; Mulder PG; Prens EP; Michel MF
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2307-11. PubMed ID: 2088186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis.
    Turner A; Pedler SJ; Carswell F; Spencer GR; Speller DC
    J Antimicrob Chemother; 1984 Nov; 14(5):521-7. PubMed ID: 6392281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis.
    Hedman A; Adan-Abdi Y; Alvan G; Strandvik B; Arvidsson A
    Clin Pharmacokinet; 1988 Jul; 15(1):57-65. PubMed ID: 3042246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
    Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation.
    Mariat C; Venet C; Jehl F; Mwewa S; Lazarevic V; Diconne E; Fonsale N; Carricajo A; Guyomarc'h S; Vermesch R; Aubert G; Bidault R; Bertrand JC; Zeni F
    Crit Care; 2006 Feb; 10(1):R26. PubMed ID: 16507147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients.
    Byl B; Baran D; Jacobs F; Herschuelz A; Thys JP
    J Antimicrob Chemother; 2001 Aug; 48(2):325-7. PubMed ID: 11481316
    [No Abstract]   [Full Text] [Related]  

  • 12. [Continuous intravenous home treatment of airway infections using ceftazidime administration via portable pump in patients with cystic fibrosis; a multicenter study].
    Bakker W; Vinks AA; Mouton JW; de Jonge P; Verzijl JG; Heijerman HG
    Ned Tijdschr Geneeskd; 1993 Nov; 137(48):2486-91. PubMed ID: 8272124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis.
    Hubert D; Le Roux E; Lavrut T; Wallaert B; Scheid P; Manach D; Grenet D; Sermet-Gaudelus I; Ramel S; Cracowski C; Sardet A; Wizla N; Deneuville E; Garraffo R
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3650-6. PubMed ID: 19528265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.
    Angus BJ; Smith MD; Suputtamongkol Y; Mattie H; Walsh AL; Wuthiekanun V; Chaowagul W; White NJ
    Br J Clin Pharmacol; 2000 May; 49(5):445-52. PubMed ID: 10792202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefepime. Pharmacokinetics and clinical response in patients with cystic fibrosis.
    Arguedas AG; Stutman HR; Zaleska M; Knupp CA; Marks MI; Nussbaum E
    Am J Dis Child; 1992 Jul; 146(7):797-802. PubMed ID: 1496945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.
    Angus BJ; Smith MD; Suputtamongkol Y; Mattie H; Walsh AL; Wuthiekanun V; Chaowagul W; White NJ
    Br J Clin Pharmacol; 2000 Aug; 50(2):184-91. PubMed ID: 10930972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
    Mouton JW; Punt N; Vinks AA
    Clin Ther; 2005 Jun; 27(6):762-72. PubMed ID: 16117983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
    Vic P; Ategbo S; Turck D; Husson MO; Launay V; Loeuille GA; Sardet A; Deschildre A; Druon D; Arrouet-Lagande C
    Arch Dis Child; 1998 Jun; 78(6):536-9. PubMed ID: 9713009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum and sputum concentrations of azlocillin, cefoperazone and ceftazidime in patients with cystic fibrosis.
    Martini N; Agostini M; Barlocco G; Bozzini L; Castellani L; Messori A; Scroccaro G; Mastella G
    J Clin Hosp Pharm; 1984 Dec; 9(4):303-9. PubMed ID: 6396321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.